Abstract PS5-03-08: Effectiveness of sacituzumab govitecan in later-line treatment of mTNBC: real-world evidence from Poland, Czech Republic, and Slovakia according to prior first-line pembrolizumab use
Justyna Żubrowska, Marcin Kubeczko, Małgorzata Pieniążek, Anna Polakiewicz-Gilowska et autres
Abstract Background Patients with metastatic triple-negative breast cancer (mTNBC) have limited treatment options and poor outcomes in later lines. Sacituzumab govitecan (SG) has shown benefit in this setting, including among those previously treated with programmed death-1 (PD-1) inhibitors. In the ASCENT trial, …
pl, hu, cz, sk (code pays fourni par la source)
0 citations
Clinical Cancer Research